Abstracted fromMedeiros
and requiring at least one molar tooth extracted were randomised to either having their ASA therapy suspended for seven days before tooth extraction and restarted the day following the surgical procedure or not having their ASA therapy suspended at any point before or after the procedure. A single dentist who was unaware of the patients' ASA therapy status performed all the extractions.
Outcome measure Outcomes were a platelet aggregation test carried out on the day of the operation and the amount of bleeding measured during the intra-operative period.
Results Bleeding was controlled with local haemostatic methods and there were no reported episodes of haemorrhaging during the intra- This paper is 'advertised' as a double-blind study. While the surgeon and the analytic team were blind to the treatment, I do not think the patients were blinded. One group continued its ASA therapy and the other group suspended ASA treatment for a week. I did not see evidence that the group who stopped ASA therapy continued on a placebo dose. I do not think this is a major flaw; however, when the investigators are not sure of their study design, it casts a long shadow on the overall quality of the study.
The duration of discontinuing ASA may not have been long enough, ie seven days, to achieve the desired therapeutic effect.
Platelets survive about ten days. If the investigators discontinued ASA for seven days, there was a persistent sub-population of platelets present with abnormal function. As such, the investigators may have underestimated the treatment effect of discontinuing ASA preoperatively.
EBL is a notoriously difficult parameter to estimate. While the authors measured intra-operative blood loss well, how did they ascertain post-operative blood loss? Additionally, I am not sure intra-operative blood loss was the best parameter to measure www.nature.com/ebd 89
